The Absence of Fucose but Not the Presence of Galactose or Bisecting N-Acetylglucosamine of Human IgG1 Complex-type Oligosaccharides Shows the Critical Role of Enhancing Antibody-dependent Cellular Cytotoxicity
Open accessThe DOI matches its Crossref record; 34 of the 34 references it cites were found in a registry or an index.
Abstract
An anti-human interleukin 5 receptor (hIL-5R) humanized immunoglobulin G1 (IgG1) and an anti-CD20 chimeric IgG1 produced by rat hybridoma YB2/0 cell lines showed more than 50-fold higher antibody-dependent cellular cytotoxicity (ADCC) using purified human peripheral blood mononuclear cells as effector than those produced by Chinese hamster ovary (CHO) cell lines. Monosaccharide composition and oligosaccharide profiling analysis showed that low fucose (Fuc) content of complex-type oligosaccharides was characteristic in YB2/0-produced IgG1s compared with high Fuc content of CHO-produced IgG1s. YB2/0-produced anti-hIL-5R IgG1 was subjected to Lens culinaris aggulutin affinity column and fractionated based on the contents of Fuc. The lower Fuc IgG1 had higher ADCC than the IgG1 before separation. In contrast, the content of bisecting GlcNAc of the IgG1 affected ADCC much less than that of Fuc. In addition, the correlation between Gal and ADCC was not observed. When the combined effect of Fuc and bisecting GlcNAc was examined in anti-CD20 IgG1, only a severalfold increase of ADCC was observed by the addition of GlcNAc to highly fucosylated IgG1. Quantitative PCR analysis indicated that YB2/0 cells had lower expression level of FUT8 mRNA, which codes alpha1,6-fucosyltransferase, than CHO cells. Overexpression of FUT8 mRNA in YB2/0 cells led to an increase of fucosylated oligosaccharides and decrease of ADCC of the IgG1. These results indicate that the lack of fucosylation of IgG1 has the most critical role in enhancement of ADCC, although several reports have suggested the importance of Gal or bisecting GlcNAc and provide important information to produce the effective therapeutic antibody.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“This is ideal as increases in fucosylation have been correlated with decreased ADCC activity and decreased FcγRIIIa and FcγRIIb binding affinity. 40 , 41 , 42 , 43”
From Dynamic pH profiles drive higher cell‐specific and volumetric productivity (2026) · cites this paper as [42]
In the citing paper
“lower cell specific productivity has been shown to allow for more mature glycoforms, including G2F. 42”
From Dynamic pH profiles drive higher cell‐specific and volumetric productivity (2026) · cites this paper as [42]
In the citing paper
“Enriching the abundance of mAb N-glycoforms with β1,4-linked galactose (Gal) can also be desirable as it has been shown to enhance complement-dependent cytotoxicity (CDC), another mechanism for the selective depletion of tumour cells by Fc activation of the complement pathway [16–21].”
From Glycoengineering Chinese hamster ovary cells: a short history (2021) · cites this paper as [16]
In the citing paper
“The addition of bisecting β1,4-linked N-acetylglucosamine (GlcNAc) by endogenous or recombinant N-acetylglucosaminyltransferase III (GnT-III in YB2/0 and CHO cells respectively) or via in vitro glycan remodelling has also been linked to increased ADCC in IgGs, albeit to a lesser extent than afucosylation [15–17].”
From Glycoengineering Chinese hamster ovary cells: a short history (2021) · cites this paper as [16]
In the citing paper
“It was reported that afucosylated Fc domain glycans of human IgG1 could enhance the binding to FcγRIIIa subtype receptors of natural killer cells (Shields et al., 2002;Shinkawa et al., 2003;Niwa et al., 2005;Iida et al., 2006;Subedi and Barb, 2016).”
From Therapeutic glycoprotein production in mammalian cells (2017) · cites this paper as Shinkawa et al., 2003
Citations
Cites
Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets
Clynes, R. A., Towers, T. L., Presta, L. G., & Ravetch, J. V. (2000) · Nature Medicine · doi:10.1038/74704 · Cited by 2,768
Cartron, G., Dacheux, L., Salles, G., Solal-Celigny, P., Bardos, P., Colombat, P., & Watier, H. (2002) · Blood · doi:10.1182/blood.v99.3.754 · Cited by 1,900
Shields, R. L., Lai, J., Keck, R., O'Connell, L. Y., Hong, K., Meng, Y. G., Weikert, S. H. A., & Presta, L. G. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m202069200 · Cited by 1,835
Deisenhofer, J. (1981) · PubMed · Cited by 1,422
Deisenhofer, J. (1981) · Biochemistry · doi:10.1021/bi00512a001 · Cited by 1,333
Parekh, R. B., Dwek, R. A., Sutton, B. J., Fernandes, D. L., Leung, A., Stanworth, D., Rademacher, T. W., Mizuochi, T., Taniguchi, T., Matsuta, K., et al. (1985) · Nature · doi:10.1038/316452a0 · Cited by 1,170
Umaña, P., Jean–Mairet, J., Moudry, R., Amstutz, H., & Bailey, J. E. (1999) · Nature Biotechnology · doi:10.1038/6179 · Cited by 764
Differential responses of human tumor cell lines to anti-p185HER2 monoclonal antibodies
Lewis, G. D., Figari, I., Fendly, B., Lee Wong, W., Carter, P., Gorman, C., & Shepard, H. M. (1993) · Cancer Immunology, Immunotherapy · doi:10.1007/bf01518520 · Cited by 498
Refined Structure of an Intact IgG2a Monoclonal Antibody,
Harris, L. J., Larson, S. B., Hasel, K. W., & McPherson, A. (1997) · Biochemistry · doi:10.1021/bi962514+ · Cited by 451
Crystallographic structure of an intact IgG1 monoclonal antibody 1 1Edited by I. A. Wilson
Harris, L. J., Skaletsky, E., & McPherson, A. (1998) · Journal of Molecular Biology · doi:10.1006/jmbi.1997.1508 · Cited by 440
Research works printed but not linked: 2
- Rademacher, 1986, Biochem. Soc. Symp., 51, 131
- Kumpel, 1994, Hum. Antib. Hybrid., 5, 143
Cited by
Items 901–1,000 of 1,000
The Role and Function of Fcγ Receptors on Myeloid Cells
Bournazos, S., Wang, T. T., & Ravetch, J. V. (2017) · ASM Press eBooks · doi:10.1128/9781555819194.ch22 · Cited by 15
Technical Basis for Nuclear Magnetic Resonance Approach for Glycoproteins
Kato, K., Yanaka, S., & Yagi, H. (2017) · Springer eBooks · doi:10.1007/978-981-10-5966-7_15 · Cited by 16
Ashida, H., Fujimoto, T., Kurihara, S., Nakamura, M., Komeno, M., Huang, Y., Katayama, T., Kinoshita, T., & Takegawa, K. (2020) · Journal of Applied Glycoscience · doi:10.5458/jag.jag.jag-2019_0016 · Cited by 14
Zahid, D., Zhang, N., Fang, H., Gu, J., Li, M., & Li, W. (2020) · Journal of Microbiology Immunology and Infection · doi:10.1016/j.jmii.2020.02.006 · Cited by 13
Afucosylated IgG Targets FcγRIV for Enhanced Tumor Therapy in Mice
Braster, R., Bögels, M., Benonisson, H., Wuhrer, M., Plomp, R., Bentlage, A. E. H., Korthouwer, R., Visser, R., Verbeek, J. S., van Egmond, M., et al. (2021) · Cancers · doi:10.3390/cancers13102372 · Cited by 18
“The effect of core fucosylation in the Fc domain of human IgG1 influences binding to both orthologue receptors, human FcγRIIIa [20] and mouse FcγRIV [21].”
BackgroundMisaki, R., Sakai, Y., Ōmasa, T., Fujiyama, K., & Seki, T. (2011) · Journal of Bioscience and Bioengineering · doi:10.1016/j.jbiosc.2011.07.002 · Cited by 16
Bisecting GlcNAc mediates the binding of annexin V to Hsp47
Gao, C., Miyoshi, E., Uozumi, N., Takamiya, R., Wang, X., Noda, K., Gu, J., Honke, K., Wada, Y., & Taniguchi, N. (2005) · Glycobiology · doi:10.1093/glycob/cwj005 · Cited by 13
“E4-PHA agarose was used as a ligand in lectin affinity chromatography (Shinkawa et al., 2003) for separating Hsp47 purified from GnT-III-transfected M31 cells based on the content of bisecting GlcNAc.”
MethodIgG glycosylation in autoimmune diseases
Kozłowska, K., Rydlewska, M., Ząbczyńska, M., & Pocheć, E. (2018) · Postępy Higieny i Medycyny Doświadczalnej · doi:10.5604/01.3001.0012.7351 · Cited by 16
Glycosylation of Therapeutic IgGs
Mimura, Y., Jefferis, R., Mimura‐Kimura, Y., Abrahams, J. L., & Rudd, P. M. (2009) · Wiley eBooks · doi:10.1002/9780470485408.ch3 · Cited by 13
Biosimilar monoclonal antibodies in lymphoma: a critical appraisal
Rioufol, C., & Salles, G. (2015) · Expert Review of Anticancer Therapy · doi:10.1586/14737140.2015.1028919 · Cited by 12
“In vitro, a low-fucose content is associated with dramatically enhanced ADCC [86].”
BackgroundInfluentialSweet Rules: Linking Glycosylation to Antibody Function
Nimmerjahn, F., & Werner, A. (2021) · Experientia supplementum · doi:10.1007/978-3-030-76912-3_12 · Cited by 14
Suzuki, H., Ohishi, T., Kaneko, M. K., & Kato, Y. (2023) · Cancers · doi:10.3390/cancers15205080 · Cited by 14
“The interaction between Fc and Fc γ RIIIa on effector cells is facilitated by a core fucose deficiency in the N -glycan in the Fc region [22].”
BackgroundThe characterization and quantitation of glycomic changes in CHO cells during a bioreactor campaign
Tep, S., Hincapie, M., & Hancock, W. S. (2012) · Biotechnology and Bioengineering · doi:10.1002/bit.24590 · Cited by 14
Fucosyltransferase 8. GDP-Fucose N-Glycan Core α6-Fucosyltransferase (FUT8)
Ihara, H., Tsukamoto, H., Gu, J., Miyoshi, E., Taniguchi, N., & Ikeda, Y. (2014) · Springer eBooks · doi:10.1007/978-4-431-54240-7_59 · Cited by 13
Prat, M., Salon, M., Allain, T., Dubreuil, O., Noel, G. L., Preisser, L., Jean, B., Cassard, L., Lemée, F., Tabah-Fisch, I. M., et al. (2021) · Cancers · doi:10.3390/cancers13081845 · Cited by 13
“Particularly core fucosylated oligosaccharides showed weaker binding to the FcγRIIIa receptor (CD16) expressed on effector cells and resulted in a decreased lytic potential [16,17].”
BackgroundInfluentialAnalytical Characterization of Monoclonal Antibodies: Linking Structure to Function
Harris, R. J., Chin, E. T., Macchi, F. D., Keck, R. G., Shyong, B., Ling, V. T., Cordoba, A. J., Marian, M., Sinclair, D., Battersby, J. E., et al. (2009) · Springer eBooks · doi:10.1007/978-0-387-76643-0_12 · Cited by 14
Yamaki, K., & Yoshino, S. (2011) · Scandinavian Journal of Immunology · doi:10.1111/j.1365-3083.2011.02598.x · Cited by 12
Tep, S., Hincapie, M., & Hancock, W. S. (2011) · Carbohydrate Research · doi:10.1016/j.carres.2011.10.005 · Cited by 12
Yamada, H., Matsumura, C., Yamada, K., Teshima, K., Hiroshima, T., Kinoshita, M., Suzuki, S., & Kakehi, K. (2017) · Electrophoresis · doi:10.1002/elps.201700014 · Cited by 12
Through the barricades: overcoming the barriers to effective antibody-based cancer therapeutics
Dalziel, M., Beers, S. A., Cragg, M. S., & Crispin, M. (2018) · Glycobiology · doi:10.1093/glycob/cwy043 · Cited by 15
Prospects for risk stratification of anti-HPA-1a alloimmunized pregnant women
Sachs, U. J. (2019) · Transfusion and Apheresis Science · doi:10.1016/j.transci.2019.102709 · Cited by 12
Carbocisteine promotes phagocytosis of apoptotic cells by alveolar macrophages
Inoue, M., Ishibashi, Y., Nogawa, H., & Yasue, T. (2011) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2011.12.026 · Cited by 12
Improving the efficacy of trastuzumab in breast cancer
Suzuki, E., & Toi, M. (2007) · Cancer Science · doi:10.1111/j.1349-7006.2007.00455.x · Cited by 13
Wang, Q., Chung, C., Rosenberg, J. N., Yu, G., & Betenbaugh, M. (2018) · Methods in molecular biology · doi:10.1007/978-1-4939-8730-6_16 · Cited by 15
Potelligent Antibodies as Next Generation Therapeutic Antibodies
Shitara, K. (2009) · YAKUGAKU ZASSHI · doi:10.1248/yakushi.129.3 · Cited by 15
Self-citationHumanized Glycosylation: Production of Biopharmaceuticals in a Moss Bioreactor
Gorr, G., & Wagner, S. (2005) · Wiley eBooks · doi:10.1002/9783527620982.ch37 · Cited by 13
Introduction: Antibody Structure and Function
Rajpal, A., Strop, P., Yeung, Y. A., Chaparro‐Riggers, J. F., & Pons, J. (2013) · Wiley eBooks · doi:10.1002/9783527675272.ch01 · Cited by 12
Crystal structure of human alpha 1,6-fucosyltransferase, FUT8
Taniguchi, N., Ihara, H., & Nakagawa, A. (2006) · Worldwide Protein Data Bank · doi:10.2210/pdb2de0/pdb · Cited by 12
Modified Therapeutic Antibodies: Improving Efficacy
Dai, J., Zhang, X., Dai, J., Yang, X.-M., & Chen, Z. (2021) · Engineering · doi:10.1016/j.eng.2020.06.030 · Cited by 14
Generation and Characterization of Native and Sialic Acid-Deficient IgE
McCraw, A. J., Gardner, R. A., Davies, A. M., Spencer, D. I. R., Grandits, M., Wagner, G. K., McDonnell, J. M., Karagiannis, S. N., Chenoweth, A. M., & Crescioli, S. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232113455 · Cited by 11
Ohkawa, Y., Kitano, M., Maeda, K., Nakano, M., Kanto, N., Kizuka, Y., Seike, M., Azuma, A., Yamaguchi, Y., Ookawara, T., et al. (2023) · Antioxidants and Redox Signaling · doi:10.1089/ars.2022.0010 · Cited by 11
“Interestingly, the elimination of the core fu-cose of the N -glycan in immunoglobulin G (IgG) can dramatically enhance the binding affinity to its receptor, Fc c RIII (Jez et al, 2012; Shinkawa et al, 2003).”
Effect of Fc core fucosylation and light chain isotype on IgG1 flexibility
Saporiti, S., Laurenzi, T., Guerrini, U., Coppa, C., Palinsky, W., Benigno, G., Palazzolo, L., Mariem, O. B., Montavoci, L., Rossi, M., et al. (2023) · Communications Biology · doi:10.1038/s42003-023-04622-7 · Cited by 16
Chemoenzymatic Labeling, Detection and Profiling of Core Fucosylation in Live Cells
Zhu, Q., Chaubard, J.-L., Geng, D., Shen, J., Ban, L., Cheung, S. T., Wei, F., Liu, Y., Sun, H., Calderon, A., et al. (2024) · Journal of the American Chemical Society · doi:10.1021/jacs.4c09303 · Cited by 11
Bosman, G. P., Stoof, I. D., Bastiaansen, H. P., van Ufford, L. Q., Dobruchowska, J. M., Langenbach, J.-W. H., Boruah, B. M., Moremen, K. W., Bentlage, A. E. H., Lissenberg‐Thunnissen, S. N., et al. (2025) · ACS Chemical Biology · doi:10.1021/acschembio.4c00807 · Cited by 11
Sahoo, A., Jones, A., Cheedarla, N., Gangadhara, S., Roy, V., Styles, T. M., Shiferaw, A., Walter, K. A., Williams, L. D., Shen, X., et al. (2022) · Science Immunology · doi:10.1126/sciimmunol.abl4102 · Cited by 11
Chen, C., Li, T., Chen, G., Chen, D., Peng, Y., Hu, B., Sun, Y., & Zeng, X. (2023) · Food Bioscience · doi:10.1016/j.fbio.2023.102393 · Cited by 12
Antibodies as clinical tools for tuberculosis
McIntyre, S., Warner, J. M., Rush, C. M., & Vanderven, H. A. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1278947 · Cited by 14
Distinctive domains and activity regulation of core fucosylation enzyme FUT8
Tomida, S., Nagae, M., & Kizuka, Y. (2024) · Biochimica et Biophysica Acta (BBA) - General Subjects · doi:10.1016/j.bbagen.2024.130561 · Cited by 11
I g E glycosylation and impact on structure and function: A systematic review
McCraw, A. J., Palhares, L. C. G. F., Hendel, J. L., Gardner, R. A., Santaolalla, A., Crescioli, S., McDonnell, J. M., Hemelrijck, M. V., Chenoweth, A. M., Spencer, D. I. R., et al. (2024) · Allergy · doi:10.1111/all.16259 · Cited by 14
Monoclonal Antibodies for Cancer Immunotherapy
Zarnani, A., Bozorgmehr, M., Shabani, M., Leila, B. Y., Ghaemimanesh, F., & Jeddi‐Tehrani, M. (2014) · Springer eBooks · doi:10.1007/978-3-662-44946-2_16 · Cited by 12
“Two independent studies have demonstrated that lack of the fucose moiety from carbohydrate on Asn-297, signifi cantly improves the binding of Ab to FcγRIII and ADCC [ 211 , 212 ].”
Glycoengineering in cancer therapeutics: a review with fucose-depleted trastuzumab as the model
Listinsky, J. J., Siegal, G. P., & Listinsky, C. M. (2012) · Anti-Cancer Drugs · doi:10.1097/cad.0b013e328359e3f4 · Cited by 14
Soman, G., Kallarakal, A. T., Michiel, D. F., Yang, X., Saptharish, N., Jiang, H., Giardina, S. L., Gilly, J. A., & Mitra, G. (2012) · mAbs · doi:10.4161/mabs.4.1.18566 · Cited by 11
Yoo, J. Y., Ko, K. S., Lee, S. Y., & Lee, K. O. (2014) · Plant Biotechnology Reports · doi:10.1007/s11816-014-0328-1 · Cited by 12
“…of immunoglobulin heavy chains (IgH) and the structure of the N-glycan influence Fc-mediated effecter functions, including interaction with Fc receptors (FcRs), ADCC and complement-dependent cytotoxicity (CDC) (Nechansky et al. 2007; Nimmerjahn and Ravetch 2008; Shinkawa et al. 2003).”
BackgroundZheng, J., Guo, Y., Ji, X., Cui, L., & He, W. (2013) · Cancer Letters · doi:10.1016/j.canlet.2013.07.036 · Cited by 12
Investigating the Role of Artemin Glycosylation
Qiu, D., Code, C., Quan, C., Gong, B.-J., Arndt, J. W., Pepinsky, B., Rand, K. D., & Houde, D. J. (2016) · Pharmaceutical Research · doi:10.1007/s11095-016-1880-x · Cited by 12
Ascites from Ovarian Cancer Induces Novel Fucosylated Proteins
Alberto-Aguilar, D. R., Hernández‐Ramírez, V. I., Osorio‐Trujillo, J. C., Gallardo‐Rincón, D., Toledo‐Leyva, A., & Talamás‐Rohana, P. (2019) · Cancer Microenvironment · doi:10.1007/s12307-019-00227-z · Cited by 13
Cell engineering for the production of hybrid-type N-glycans in HEK293 cells
Leng, J.-X., Ren, W., Li, Y., Yang, G., Gao, X., & Fujita, M. (2021) · The Journal of Biochemistry · doi:10.1093/jb/mvab051 · Cited by 11
Cloning, expression and characterization of Bombyx mori α1,6-fucosyltransferase
Ihara, H., Okada, T., & Ikeda, Y. (2014) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2014.06.087 · Cited by 12
Antibody–Cytotoxic Compound Conjugates for Oncology
Vater, C. A., & Goldmacher, V. S. (2009) · Springer eBooks · doi:10.1007/978-1-4419-0507-9_9 · Cited by 12
Hiranyakorn, M., Iwamoto, S., Hoshinoo, A., Tsumura, R., Takashima, H., Yasunaga, M., & Manabe, S. (2023) · ACS Omega · doi:10.1021/acsomega.3c02374 · Cited by 10
Development of a FUT8 Inhibitor with Cellular Inhibitory Properties
Manabe, Y., Takebe, T., Kasahara, S., Hizume, K., Kabayama, K., Kamada, Y., Asakura, A., Shinzaki, S., Takamatsu, S., Miyoshi, E., et al. (2024) · Angewandte Chemie International Edition · doi:10.1002/anie.202414682 · Cited by 17
Formolo, T., Heckert, N. A., & Phinney, K. W. (2014) · Analytical and Bioanalytical Chemistry · doi:10.1007/s00216-014-8043-x · Cited by 10
Konstantinus, I. N., Gamieldien, H., Mkhize, N. N., Kriek, J., & Passmore, J.-A. S. (2016) · Journal of Immunological Methods · doi:10.1016/j.jim.2016.04.006 · Cited by 11
Fucose-Targeted Glycoengineering of Pharmaceutical Cell Lines
Ogorek, C., Jordan, I., Sandig, V., & von Horsten, H. H. (2012) · Methods in molecular biology · doi:10.1007/978-1-61779-974-7_29 · Cited by 9
Does Glyphosate Acting as a Glycine Analogue Contribute To ALS?
Seneff, S. (2016) · JOURNAL OF BIOINFORMATICS AND PROTEOMICS REVIEW · doi:10.15436/2381-0793.16.1173 · Cited by 11
“Lack of core fucosylation in IgG results in a 50- to 100fold increase in antibody-dependent cellular cytotoxicity[86].”
BackgroundRameez, S., Gowtham, Y. K., Nayar, G., & Mostafa, S. S. (2021) · Biotechnology Progress · doi:10.1002/btpr.3176 · Cited by 11
“ADCC activity of up to 50-fold have been attributed to increases in the afucosylated species in N-glycosylation of mAbs.(11) The reduction in ADCC activity and the reduced FcγRIIIa binding of the biosimilar DS compared to the innovator DP indicated that modulating N-glycosylation levels, especially afucosylation level…”
BackgroundCrowley, A. R., Osei‐Owusu, N. Y., Dekkers, G., Gao, W., Wuhrer, M., Magnani, D. M., Reimann, K. A., Pincus, S. H., Vidarsson, G., & Ackerman, M. E. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.754710 · Cited by 13
N-glycan branching enzymes involved in cancer, Alzheimer's disease and COPD and future perspectives
Taniguchi, N., Ohkawa, Y., Maeda, K., Kanto, N., Johnson, E. L., & Harada, Y. (2022) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2022.09.027 · Cited by 11
Reinert, T., Gahoual, R., Mignet, N., Kulus, A., Allez, M., Houzé, P., & François, Y. (2023) · Journal of Pharmaceutical and Biomedical Analysis · doi:10.1016/j.jpba.2023.115446 · Cited by 11
An Fc-modified monoclonal antibody as novel treatment option for pancreatic cancer
Lutz, M. S., Wang, K., Jung, G., Salih, H. R., & Hagelstein, I. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1343929 · Cited by 11
Enhancement of antibody production by the addition of Coenzyme-Q10
Konno, Y., Aoki, M., Takagishi, M., Sakai, N., Koike, M., Wakamatsu, K., & Hosoi, S. (2010) · Cytotechnology · doi:10.1007/s10616-010-9330-9 · Cited by 9
“Minimizing the cost of goods and maximizing antibody activity are therefore active areas of research in the development of MAbs for therapeutic use (Shields et al. 2002; Shinkawa et al. 2003; Wurm 2004).”
BackgroundFunction characterization of a glyco-engineered anti-EGFR monoclonal antibody cetuximab in vitro
Yi, C., Ruan, C., Wang, H., Xu, X., Zhao, Y., Fang, M., Ji, J., Gu, X., & Gao, C. (2014) · Acta Pharmacologica Sinica · doi:10.1038/aps.2014.77 · Cited by 13
Characterization of Therapeutic Proteins
Struble, E. B., Kirschbaum, N., Liu, J., Marszal, E., & Shapiro, M. (2016) · Topics in medicinal chemistry · doi:10.1007/7355_2015_5005 · Cited by 10
Boesch, A. W., Kappel, J. H., Mahan, A. E., Chu, T. H., Crowley, A. R., Osei‐Owusu, N. Y., Alter, G., & Ackerman, M. E. (2018) · Biotechnology and Bioengineering · doi:10.1002/bit.26545 · Cited by 11
“To separate IgGs by Fc glycoforms, researchers have employed carbohydrate-binding lectins to enrich IgG Fcs that are sialylated (Kaneko, Nimmerjahn, & Ravetch, 2006), fucosylated (Shinkawa et al., 2003; Tojo et al., 2009), or mannosylated (Tojo et al., 2009).”
BackgroundFournier, N., Jacque, É., Fontayne, A., Derache, D., Dupont, G., Verhaeghe, L., Baptista, L., Dehenne, A., Dezetter, A.-S., Terrier, A., et al. (2018) · mAbs · doi:10.1080/19420862.2018.1451283 · Cited by 10
Development of Large Scale Silkworm-rearing Technologies for the GMP Production of Biologics
Tomita, M. (2018) · YAKUGAKU ZASSHI · doi:10.1248/yakushi.17-00202-2 · Cited by 10
Fully galactosyl-fucosyl-bisected IgG1 reduces anti-HBV efficacy and liver histological improvement
Ho, C.-H., Chen, S., Tsai, H., Wu, I., & Chang, T. (2019) · Antiviral Research · doi:10.1016/j.antiviral.2018.12.021 · Cited by 10
Targeting CD20: teaching an old dog new tricks
Sharman, J. P. (2019) · Hematology · doi:10.1182/hematology.2019000031 · Cited by 10
Bishop, M. W., Hutson, P. R., Hank, J. A., Sondel, P. M., Furman, W. L., Meagher, M. M., Navid, F., & Santana, V. M. (2020) · mAbs · doi:10.1080/19420862.2020.1773751 · Cited by 11
“18K322A is produced in a YB2/0 rat myeloma cell line that reduces fucosylation and enhances ADCC activity.(4,5) We have previously reported the results of 38 patients with recurrent/refractory neuroblastoma treated on a Phase 1 trial with hu14.”
ResultInui, T., Kawamura, N., Nakama, R., Inui, A., & Katsuura, G. (2022) · Frontiers in Nutrition · doi:10.3389/fnut.2022.852355 · Cited by 11
Abe, M., Shimaoka, H., Fukushima, M., & Nishimura, S. (2011) · Polymer Journal · doi:10.1038/pj.2011.125 · Cited by 10
Aglycosylated antibodies and the methods of making and using them: WO2008030564
Jefferis, R. (2009) · Expert Opinion on Therapeutic Patents · doi:10.1517/13543770802592408 · Cited by 11
“These effector ligands include three structurally homologous cellular Fc receptor types (Fc γ RI, Fc γ RIIa, Fc γ RIIb, Fc γ RIIIa and Fc γ RIIIb; as cellular receptors they are also designated CD64, CD32a, CD32b, CD16a and CD16b), the C1q component of complement and the neonatal Fc receptor (FcRn) [4,5,6-11] ; the la…”
BackgroundResultInfluentialHammura, K., Ishikawa, A., V., R. K. H., Miyoshi, R., Yokoi, Y., Tanaka, M., Hinou, H., & Nishimura, S. (2018) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.8b00127 · Cited by 11
At-line high throughput site-specific glycan profiling using targeted mass spectrometry
Chi, B., Veyssier, C. S., Kasali, T., Uddin, F., & Sellick, C. A. (2020) · Biotechnology Reports · doi:10.1016/j.btre.2020.e00424 · Cited by 10
Satoh, M., Shitara, K., & Hanai, N. (2007) · Elsevier eBooks · doi:10.1016/b978-044451967-2/00124-0 · Cited by 10
Self-citationMiyazaki, T., Miyashita, R., Nakamura, S., Ikegaya, M., Kato, T., & Park, E. Y. (2019) · Insect Biochemistry and Molecular Biology · doi:10.1016/j.ibmb.2019.103254 · Cited by 10
Current and future use of antibody-based passive immunity to prevent or control HBV/HDV infections
Gehring, A. J., & Salimzadeh, L. (2024) · Antiviral Research · doi:10.1016/j.antiviral.2024.105893 · Cited by 12
Dixon, K. J., Snyder, K. M., Khaw, M. J., Hullsiek, R., Davis, Z., Matson, A. W., Shirinbak, S., Hancock, B., Bjordahl, R., Hosking, M., et al. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1407567 · Cited by 11
Posttranslational modifications of heterologous proteins expressed in Nicotiana benthamiana
Göritzer, K., Kallolimath, S., & Strasser, R. (2025) · Plant Biotechnology Journal · doi:10.1111/pbi.70176 · Cited by 9
“This N-glycan is important for effector functions by modulating the interaction with Fc c -receptors (Shields et al ., 2002; Shinkawa et al ., 2003).”
Advances in cancer research on FUT8 molecular mechanisms and clinical applications
Ma, Q., Liu, Y., Fan, Q., Zhu, X., Yang, D., & Zhao, Z. (2025) · International Journal of Surgery · doi:10.1097/js9.0000000000002669 · Cited by 12
“IgG1 produced by the Y2B/0 rat cell line, which naturally has low FUT8 enzyme activity, demonstrated significantly enhanced ADCC compared to antibodies produced in control Chinese hamster ovary (CHO) cells [ 94 ] .”
From Silkroad to Bioroad–Silkworm Biotechnology–
Park, E. Y. (2025) · Protein Expression and Purification · doi:10.1016/j.pep.2025.106762 · Cited by 9
Ishido, Y., Kanbayashi, N., Fujii, N., Okamura, T., Haino, T., & Onitsuka, K. (2020) · Chemical Communications · doi:10.1039/c9cc10030j · Cited by 9
Antibody glycosylation directs innate and adaptive immune collaboration
Polmear, J., & Good‐Jacobson, K. L. (2021) · Current Opinion in Immunology · doi:10.1016/j.coi.2021.12.002 · Cited by 12
Recent advances in the treatment of childhood asthma: a clinical pharmacology perspective
Bahmani, A. H. A., Abdel‐Aziz, M. I., der Zee, A. H. M., & Vijverberg, S. J. H. (2022) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2022.2131537 · Cited by 10
“affinity to bind to the FcγRIIIa receptor of natural killer (NK) cells [42,43].”
BackgroundMakiyama, J., Ishitsuka, K., Munakata, W., Maruyama, D., & Nagai, H. (2023) · Japanese Journal of Clinical Oncology · doi:10.1093/jjco/hyad108 · Cited by 10
Tanaka, T., Suzuki, H., Ohishi, T., Kaneko, M. K., & Kato, Y. (2023) · Cancer Science · doi:10.1111/cas.16008 · Cited by 10
“40,41 This technique is also applied to clinically approved afucosylated mAb targeting CCR4, mogamulizumab (Poteligeo).”
MethodSuzuki, H., Ohishi, T., Tanaka, T., Kaneko, M. K., & Kato, Y. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25158386 · Cited by 17
“Therefore, a core fucose deficiency on the Fc N -glycan has been shown to enhance the binding to Fc γ R on effector cells [17] and exert potent antitumor effects [18].”
BackgroundDu, Y., May, K. M. L., Xu, W., & Liu, H. (2012) · Journal of the American Society for Mass Spectrometry · doi:10.1007/s13361-012-0397-8 · Cited by 9
“For example, it has been found that absence of the core-fucose can significantly enhance the FcγRIIIa binding affinity of IgG1, resulting in increased antibody-dependent cellular cytotoxicity (ADCC) [5–7].”
BackgroundExploiting natural anti-carbohydrate antibodies for therapeutic purposes
Bello‐Gil, D., & Máñez, R. (2015) · Biochemistry (Moscow) · doi:10.1134/s0006297915070044 · Cited by 9
“Thus, the removal of α1,6 fucose from oligosaccharides attached to Asn297 of human IgG1 Fc greatly increased ADCC, producing a stronger effect than any other structural change in the Fc oligosaccharides [77, 78].”
BackgroundAdult T-Cell Leukemia-Lymphoma
Munakata, W., & Tobinai, K. (2018) · Cancer treatment and research · doi:10.1007/978-3-319-99716-2_7 · Cited by 11
Lin, M., Shen, C., Lin, Y.-J., Chou, M., Pham, N. N., Chang, Y., Chang, C.-W., Hwu, J. R., Nguyen, M. T. T., & Hu, Y. (2021) · Journal of the Taiwan Institute of Chemical Engineers · doi:10.1016/j.jtice.2021.03.040 · Cited by 10
Gomathinayagam, S., Laface, D., Houston-Cummings, N. R., Mangadu, R., Moore, R., Shandil, I., Sharkey, N., Li, H., Stadheim, T. A., & Zha, D. (2015) · Journal of Biotechnology · doi:10.1016/j.jbiotec.2015.05.005 · Cited by 9
Liang, Y., Wang, T., Gao, R., Jia, X., Ji, T., Shi, P., Xue, J., Yang, A., Chen, M., & Han, P. (2022) · Pathology & Oncology Research · doi:10.3389/pore.2022.1610116 · Cited by 9
“Recently, increasing evidence has supported the crucial implication of α1,6-fucosylation by FUT8 in tumor growth and malignancy, antibody-dependent cellular cytotoxicity, as well as cell adhesion and cancer metastasis (11, 14-17).”
BackgroundSuzuki, H., Ohishi, T., Asano, T., Tanaka, T., Saito, M., Mizuno, T., Yoshikawa, T., Kawada, M., Kaneko, M. K., & Kato, Y. (2022) · Oncology Reports · doi:10.3892/or.2022.8366 · Cited by 10
“Therefore, B type dog IgG was converted and a defucosylated mAb was produced, which has been shown to exhibit more potent ADCC activity through binding to Fc γ RIIIa on NK cells (59).”
Rish, A. J., Huang, Z., Siddiquee, K., Xu, J., Anderson, C. A., Borys, M., & Khetan, A. (2023) · Processes · doi:10.3390/pr11010223 · Cited by 10
TNF receptor II fusion protein with tandemly repeated Fc domains
Nagashima, H., Kaneko, K., Yamanoi, A., Motoi, S., Konakahara, S., Kohroki, J., & Masuho, Y. (2011) · The Journal of Biochemistry · doi:10.1093/jb/mvq149 · Cited by 9
Immunomodulation in the treatment of haematological malignancies
Cesco-Gaspere, M., Morris, E. C., & Stauss, H. J. (2009) · Clinical and Experimental Medicine · doi:10.1007/s10238-009-0037-1 · Cited by 10
“Antibodies with improved binding affinity to activating FcR can be produced by site-directed mutagenesis of the Fc region [32] or by modification of the naturally occurring glycosylation site in the Fc region [ 33 ].”
BackgroundNalivaiko, K., Hofmann‐Apitius, M., Kober, K., Teichweyde, N., Krammer, P. H., Rammensee, H., Große‐Hovest, L., & Jung, G. (2015) · Molecular Therapy · doi:10.1038/mt.2015.209 · Cited by 10
Methods to Determine the Level of Afucosylation in Recombinant Monoclonal Antibodies
Shen, Y., & Liu, H. (2010) · Analytical Chemistry · doi:10.1021/ac102332f · Cited by 9
Dynamic pH profiles drive higher cell‐specific and volumetric productivity
Klaubert, S. R., Chitwood, D. G., Peng, D., Redman, E., Anderson, J. Y. L., Sandoval, N. R., & Harcum, S. W. (2026) · Biotechnology Progress · doi:10.1002/btpr.70080 · Cited by 3
Metadata
- Authors
- Shinkawa, T., Nakamura, K., Yamane, N., Shoji-Hosaka, E., Kanda, Y., Sakurada, M., Uchida, K., Anazawa, H., Satoh, M., Yamasaki, M., Hanai, N., & Shitara, K.
- Affiliations
- Kyowa Kirin (Japan) (JP)
- Corresponding author
- Shitara, Kenya
- ORCID
- Uchida, Kazuhisa
- Venue
- Journal of Biological Chemistry
- Publisher
- Elsevier BV
- Published
- 2003-01
- Volume
- 278
- Issue
- 5
- Pages
- 3466-3473
- ISSN
- 0021-9258 (ISSN-L)
- OpenAlex
- W2084136419
- Cited by
- 1,413
- References
- 33
- Citations by year
- 2026: 37 · 2025: 47 · 2024: 55 · 2023: 45 · 2022: 77 · 2021: 78 · 2020: 87 · 2019: 70 · 2018: 83 · 2017: 77 · 2016: 71 · 2015: 72 · 2014: 78 · 2013: 56 · 2012: 67
- FWCI
- 14.25
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- creativecommons.org/licenses/by/4.0/ (vor, 6498 d)
- Locations
- Journal of Biological Chemistry (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Glycosylation and Glycoproteins Research
- Life Sciences › Immunology and Microbiology › Immunology › Monoclonal and Polyclonal Antibodies Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Viral Infectious Diseases and Gene Expression in Insects
- Keywords
- antibody-dependent cellular cytotoxicity, fucosylation, bisecting N-acetylglucosamine, galactose, FUT8, alpha-1,6-fucosyltransferase, humanized monoclonal antibody, CHO cell expression, antibody glycosylation, therapeutic antibodies
- MeSH terms
- Acetylglucosamine, Animals, Antibody-Dependent Cell Cytotoxicity, Base Sequence, Carbohydrate Conformation, Carbohydrate Sequence, Cell Line, Chromatography, Affinity, Fucose, Galactose, Cricetinae, Humans, Immunoglobulin G, Molecular Sequence Data, Oligosaccharides, Recombinant Fusion Proteins, Transfection, Polymerase Chain Reaction, CHO Cells, DNA Primers, Lectins, Rats
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.